Free Trial

Genmab A/S (NASDAQ:GMAB) Short Interest Up 40.0% in February

Genmab A/S logo with Medical background
Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) was the recipient of a large increase in short interest in February. As of February 28th, there was short interest totalling 2,310,000 shares, an increase of 40.0% from the February 13th total of 1,650,000 shares. Based on an average daily volume of 1,370,000 shares, the short-interest ratio is presently 1.7 days. Currently, 0.4% of the shares of the company are short sold.

Genmab A/S Stock Up 0.2 %

Shares of GMAB stock traded up $0.04 on Wednesday, reaching $20.24. The company had a trading volume of 800,959 shares, compared to its average volume of 906,407. The business's 50-day moving average is $21.18 and its 200 day moving average is $22.28. Genmab A/S has a one year low of $18.64 and a one year high of $31.02. The stock has a market capitalization of $13.40 billion, a PE ratio of 11.63, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, sell-side analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its stake in shares of Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after purchasing an additional 939 shares during the last quarter. Lindbrook Capital LLC lifted its holdings in Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after buying an additional 950 shares during the period. GAMMA Investing LLC grew its position in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after buying an additional 1,051 shares during the last quarter. Barclays PLC increased its stake in shares of Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after buying an additional 2,285 shares during the period. Finally, Cromwell Holdings LLC raised its position in shares of Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after acquiring an additional 2,496 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on GMAB shares. Sanford C. Bernstein upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Finally, BNP Paribas raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $41.33.

Get Our Latest Stock Report on Genmab A/S

Genmab A/S Company Profile

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Featured Stories

Should You Invest $1,000 in Genmab A/S Right Now?

Before you consider Genmab A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.

While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

SMCI’s Rally Isn’t Over – Here’s Why It Could Hit $100!
7 Flying Car Stocks to Buy Before the Sector Really Takes Off
Institutions Are Dumping These 3 Stocks—Should You?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads